---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-029639"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T21:46:46.315093+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics enters $75M ATM equity offering with TD Cowen, terminates prior Oppenheimer facility

## Summary
- Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.
- Commission to TD Cowen is up to 3% of gross proceeds from sales.
- Terminated prior ATM agreement with Oppenheimer (originally $50M) effective June 4, 2025; no penalties.
- Offering is made under existing effective S-3 registration statement (File No. 333-271225).

## SEC filing metadata
- accession: 0001628280-25-029639
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025029639/0001628280-25-029639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025029639/avtx-20250603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-029639
- JSON: https://secwatch.observer/filing/0001628280-25-029639.json
- Plain text: https://secwatch.observer/filing/0001628280-25-029639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.